睿智医药8月27日获融资买入3889.76万元，融资余额2.84亿元

Core Insights - On August 27, Ruizhi Pharmaceutical experienced a decline of 4.18% with a trading volume of 388 million yuan, indicating a significant market reaction [1] - The company reported a net financing outflow of 8.82 million yuan on the same day, with a total financing and securities balance of 284 million yuan, which is 4.60% of its market capitalization [1] - The company’s main business segments include pharmacodynamics (56.39%), chemical business (26.41%), and macromolecule business (16.23%) [1][2] Financing and Trading Data - On August 27, the financing buy-in amount for Ruizhi Pharmaceutical was 38.89 million yuan, while the financing repayment was 47.72 million yuan, resulting in a net financing outflow [1] - The current financing balance of 284 million yuan is above the 90th percentile of the past year, indicating a high level of financing activity [1] - The short selling data shows a repayment of 600 shares with no shares sold on that day, and a short selling balance of 11,030 yuan, which is above the 60th percentile of the past year [1] Shareholder and Financial Performance - As of August 8, the number of shareholders for Ruizhi Pharmaceutical was 52,500, a decrease of 18.89%, while the average number of circulating shares per person increased by 23.28% to 9,467 shares [2] - For the first quarter of 2025, the company achieved a revenue of 261 million yuan, representing a year-on-year growth of 11.37%, and a net profit attributable to shareholders of 6.64 million yuan, up 126.09% year-on-year [2] - Since its A-share listing, the company has distributed a total of 180 million yuan in dividends, with no dividends paid in the last three years [3]